Evidence map›Paper›PMID 32588337›Full record

ArticleThe patient2020

The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.

Edward J D Webb, David Meads, Ieva Eskytė, Helen L Ford, Hilary L Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue H Pavitt and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in The patient, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Edward J D WebbLeeds Institute of Health Sciences, University of Leeds, Leeds, UK. e.j.d.webb@leeds.ac.uk.ORCID http://orcid.org/0000-0001-7918-839X
David MeadsLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Ieva EskytėSchool of Law, University of Leeds, Leeds, UK.
Helen L FordLeeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID http://orcid.org/0000-0002-4156-5046
Hilary L BekkerLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.ORCID http://orcid.org/0000-0003-1978-5795
Jeremy ChatawayQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, WC1B 5EH, UK.ORCID http://orcid.org/0000-0001-7286-6901
George PepperShift.Ms, London, UK.
Joachim MartiCentre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-5763-3704
Yasmina OkanCentre for Decision Research, Leeds University Business School, University of Leeds, Leeds, UK.
Sue H PavittDental Translational and Clinical Research Unit, School of Dentistry, University of Leeds, Leeds, UK.
Klaus SchmiererThe Blizard Institute (Neuroscience, Surgery & Trauma), Queen Mary University of London, Barts and The London School of Medicine & Dentistry, London, UK.ORCID http://orcid.org/0000-0002-9293-8893
Ana ManzanoSchool of Sociology and Social Policy, University of Leeds, Leeds, UK.
University of Leeds · GBQueen Mary University of London · GBCentre universitaire de médecine générale et santé publique, Lausanne · CHLeeds Teaching Hospitals NHS Trust · GBShift (United Kingdom) · GB

Funding

Cancer Research UK 57775/A22183Cancer Research UK C57775/A22182Department of Health
6 · The paper itself

Abstract

backgroundRelapsing-remitting multiple sclerosis (RRMS) is an incurable disease characterised by relapses (periods of function loss) followed by full or partial recovery, and potential permanent disability over time. Many disease-modifying treatments (DMTs) exist that help reduce relapses and slow disease progression. Most are contraindicated during conception/pregnancy and some require a discontinuation period before trying to conceive. Although around three-quarters of people with RRMS are women, there is limited knowledge about how reproductive issues impact DMT preference.

objectiveThe aim of this study was to measure the preferences for DMTs of women with RRMS who are considering pregnancy.

designAn online discrete choice experiment (DCE).

methodsParticipants chose between two hypothetical DMTs characterised by a set of attributes, then indicated if they preferred their choice to no treatment. Attributes were identified from interviews and focus groups with people with RRMS and MS professionals, as well as literature reviews, and included the probability of problems with pregnancy, discontinuation of DMTs, and breastfeeding safety. In each DCE task, participants were asked to imagine making decisions in three scenarios: now; when trying to conceive; and when pregnant. ANALYSIS: Two mixed logit models were estimated, one to assess the statistical significance between scenarios and one in maximum acceptable risk space to allow comparison of the magnitudes of parameters between scenarios. SAMPLE: Women with RRMS who were considering having a child in the future, recruited from a UK MS patient register.

resultsSixty respondents completed the survey. Participants preferred no treatment in 12.6% of choices in the 'now' scenario, rising significantly to 37.6% in the 'trying to conceive' scenario and 60.3% in the 'pregnant' scenario (Kruskal-Wallis p < 0.001). This pattern corresponds with results from models that included a no-treatment alternative-specific constant (ASC) capturing differences between taking and not taking a DMT not specified by the attributes. The ASC was lower in the trying to conceive scenario than in the now scenario, and lower still in the pregnant scenario, indicating an intrinsic preference for no treatment. Participants also placed relatively less preference on reducing relapses and avoiding disease progression in the trying to conceive and pregnant scenarios compared with a lower risk of problems with pregnancy. In the trying to conceive scenario, participants' preference for treatments with shorter washout periods increased.

conclusionWomen with RRMS considering having a child prefer DMTs with more favourable reproduction-related attributes, even when not trying to conceive. Reproductive issues also influenced preferences for DMT attributes not directly related to pregnancy, with preferences dependent on the life circumstances in which choices were made. The design of the DCE highlights the benefits of considering the scenario in which participants make choices, as they may change over time.

Indexed as

Choice BehaviorDrug-Related Side Effects and Adverse ReactionsPatient PreferenceAdultFemaleFocus GroupsHumansInterviews as TopicMultiple Sclerosis, Relapsing-RemittingPregnancyQualitative Research

Identifiers

PMID32588337
OpenAlexW3037810220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.